Search

Your search keyword '"Patt, Yehuda Z."' showing total 93 results
Start Over Author "Patt, Yehuda Z." Publication Type Academic Journals
93 results on '"Patt, Yehuda Z."'

1. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma

Author

Hassan, Manal M., Botrus, Gehan, Abdel-Wahab, Reham, Wolff, Robert A., Li, Donghui, Tweardy, David, Phan, Alexandria T., Hawk, Ernest, Javle, Milind, Lee, Ju-Seog, Torres, Harrys A., Rashid, Asif, Lenzi, Renato, Hassabo, Hesham M., Abaza, Yasmin, Shalaby, Ahmed S., Lacin, Sahin, Morris, Jeffrey, Patt, Yehuda Z., Amos, Christopher I., Khaderi, Saira A., Goss, John A., Jalal, Prasun K., and Kaseb, Ahmed O.

Published
2017
Full Text
View/download PDF

4. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction

Author

Hassan, Manal M., Kaseb, Ahmed, Etzel, Carol J., El-Serag, Hashem, Spitz, Margaret R., Chang, Ping, Hale, Katherine S., Liu, Mei, Rashid, Asif, Shama, Mohamed, Abbruzzese, James L., Loyer, Evelyne M., Kaur, Harmeet, Hassabo, Hesham M., Vauthey, Jean-Nicolas, Wray, Curtis J., Hassan, Basmah S., Patt, Yehuda Z., Hawk, Ernest, Soliman, Khalid M., and Li, Donghui

Published
2013
Full Text
View/download PDF

5. Feasibility of Adjuvant Hepatic Arterial Infusion of Chemotherapy After Radiofrequency Ablation With or Without Resection in Patients With Hepatic Metastases From Colorectal Cancer

Author

Scaife, Courtney L., Curley, Steven A., Izzo, Francesco, Marra, Paolo, Delrio, Paolo, Daniele, Bruno, Cremona, Franco, Gershenwald, Jeffrey E., Chase, Judy L., Lozano, Richard D., Patt, Yehuda Z., Fornage, Bruno D., Vauthey, Jean Nicolas, Woodall, Misty L., Gonzalez, Karen B., and Ellis, Lee M.

Published
2003
Full Text
View/download PDF

6. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma

Author

Kaseb, Ahmed O., Shindoh, Junichi, Patt, Yehuda Z., Roses, Robert E., Zimmitti, Giuseppe, Lozano, Richard D., Hassan, Manal M., Hassabo, Hesham M., Curley, Steven A., Aloia, Thomas A., Abbruzzese, James L., and Vauthey, Jean-Nicolas

Published
2013
Full Text
View/download PDF

9. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: Case-control study

Author

Hassan, Manal M., Spitz, Margaret R., Thomas, Melanie B., El-Deeb, Adel S., Glover, Katrina Y., Nguyen, Nga T., Chan, Wenyaw, Kaseb, Ahmed, Curley, Steven A., Vauthey, Jean-Nicolas, Ellis, Lee M., Abdalla, Eddie, Lozano, Richard D., Patt, Yehuda Z., Brown, Thomas D., Abbruzzese, James L., and Li, Donghui

Published
2008
Full Text
View/download PDF

24. Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer.

Author

Araujo‐Mino, Emilio P., Patt, Yehuda Z., Murray‐Krezan, Cristina, Hanson, Joshua A., Bansal, Pranshu, Liem, Ben J., Rajput, Ashwani, Fekrazad, M. Houman, Heywood, Glenory, and Lee, Fa Chyi

Subjects
ANAL surgery, RECTUM tumors, THERAPEUTIC use of antimetabolites, ANTIMETABOLITES, CANCER patients, CLINICAL trials, COMBINED modality therapy, CONFIDENCE intervals, DIARRHEA, DRUG tolerance, LIVER, NONSTEROIDAL anti-inflammatory agents, RECTAL diseases, SKIN inflammation, SURVIVAL, CYCLOOXYGENASE 2, OXALIPLATIN, TREATMENT effectiveness, CHEMORADIOTHERAPY, DIAGNOSIS, PROGNOSIS, THERAPEUTICS, TUMOR treatment
Abstract

Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2018
Full Text
View/download PDF

25. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.

Author

Patt, Yehuda Z., Murad, Waheed, Fekrazad, Mohammed H., Baron, Ari D., Bansal, Pranshu, Boumber, Yanis, Steinberg, Kim, Lee, Sang‐Joon, Bedrick, Ed, Du, Ruofei, and Lee, Fa Chyi

Subjects
*LIVER cancer, *OXALIPLATIN, *CHOLANGIOCARCINOMA, *ERLOTINIB, *EPIDEMIOLOGY of cancer, *COMBINATION drug therapy, *PUBLIC health, *THERAPEUTICS
Abstract

Hepatocellular Carcinoma ( HCC) incidence is increasing in the USA. Gemcitabine (G) and oxaliplatin (O) are active in HCC and biliary duct cancer ( BDC). Erlotinib (E) is an EGFR tyrosine kinase inhibitor ( TKI) with known activity against both. We sought to evaluate the efficacy of the combination G+O+E. Patients with either of the two diagnosis were treated in a phase II trial. Simons 2 stage design was used. A disease-control rate ( DCR), complete response ( CR) + partial response ( PR)+ stable disease ( SD) at 24 weeks of ≤20% and >40% (P0 and P1 of 0.2 and 0.4, respectively) were set as undesirable (null) and desirable results. 26 HCC and 7 BDC patients were accrued. In HCC, 1 PR, 10 SD, and 9 PDs were seen. DCR in HCC was 42%. Among seven (7) patients with BDC, one patient was not evaluable; one achieved a long lasting PR, and five patients had SD and DCR was 86%. Median overall survival ( OS) times and progression-free survivals ( PFS) were 196 and 149 days in HCC and 238 days and not reached in BDC. PFS at 26 weeks in HCC was 41% and at 21 weeks in BDC was 60%. Grade 3 toxicities in >5% of patients were fatigue (12.9%), neutropenia (9.6%), thrombocytopenia (9.6%), and diarrhea (6.4%). G+O+E exceeded both preset P0a and P1 of the primary objective with a PFS of 41% at 26 weeks for HCC and preliminary BDC data may warrant further investigations. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

26. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge

Author

Mavligit, Giora M., Charnsangavej, Chuslip, Carrasco, Humberto, Patt, Yehuda Z., Benjamin, Robert S., and Wallace, Sidney

Subjects
Metastasis -- Case studies, Head and neck tumors -- Care and treatment, Melanoma -- Diagnosis, Cisplatin -- Dosage and administration, Liver cancer -- Care and treatment
Abstract

ABSTRACT: Thirty patients with ocular melanoma metastatic to the liver were treated by hepatic arterial chemoembolization using an admixture of cisplatin and polyvinyl sponge. Tumor regression was complete in one patient and partial (>50%) in 13 patients. The total response rate was 46%. The median survival for the entire group was 11 months (95% confidence interval, nine to 18 months). Treatment-related morbidity was short-lived and included primarily severe upper right quadrant abdominal pain, transient paralytic ileus, and nonicteric hepatitis. Hepatic arterial chemoembolization provided effective palliation, with good-quality survival among 46% of patients with ocular melanoma metastatic to the liver.

Published
1988

27. A Randomized, Phase II Trial of Standard Triweekly Compared with Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer: XELOX-A-DVS (Dense Versus Standard)

Author

Hurwitz, Herbert, Mitchell, Edith P., Cartwright, Thomas, Kwok, Ambrose, Hu, Sylvia, Mckenna, Edward, and Patt, Yehuda Z.

Abstract

Background. Capecitabine administered for 7 days biweekly with oxaliplatin (XELOX) biweekly has been reported to have activity and safety profiles similar to those of standard capecitabine given for 14 days triweekly. Multiple studies have shown that the addition of bevacizumab to 5-fluorouracil- based chemotherapy is active and well tolerated. Methods. Patients with metastatic colorectal cancer (mCRC) were randomized to XELOX plus bevacizumab using a standard triweekly cycle (Q3W) or a dose-dense biweekly cycle (Q2W) schedule. The primary endpoint was the progression-free survival (PFS) interval. This trial is registered on ClinicalTrials.gov (identifier, NCT00159432). Results. In total, 435 U.S. patients were randomized. The median PFS intervals were 9.6 months in the Q3W group and 9.1 months in the Q2Wgroup. The median overall survival times were 28.4 months and 22.1 months and the median times to treatment failure were 5.5 months and 3.4 months, respectively. Overall, gastrointestinal disorders were the most common (93%) adverse event (AE). Grade 3 or 4 AEs occurred in 75% and 81% of patients in the Q3W and Q2W groups, respectively. Treatment discontinuation as a result of diarrhea (5% versus 10%) and hand--foot syndrome (2% versus 9%) was less common in the Q3W group than in the Q2W group, respectively. Conclusions. Based on these results, the first-line treatment of U.S. patients with mCRC using a biweekly combination of XELOX and bevacizumab at the doses studied cannot be recommended. XELOX Q3W remains the preferred schedule for the management of mCRC. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

32. Does Aflatoxin B1 Play a Role in the Etiology of Hepatocellular Carcinoma in the United States?

Author

Hoque, Ashraful, Patt, Yehuda Z., Yoffe, Boris, Groopman, John D., Greenblatt, Marc S., Zhang, Yu-Jing, and Santella, Regina M.

Subjects
*AFLATOXINS, *LIVER cancer, *ETIOLOGY of cancer, *ETIOLOGY of diseases, *PHYSIOLOGY
Abstract

Studies the role of aflatoxin B1 (AFB1) in the etiology of liver carcinoma in the United States. Risk factors from previous research; Search for AFB1 adducts and -53 alterations by immunoassays and codon 249 p53 mutation by restriction enzyme analysis; Recommended further investigations.

Published
1999
Full Text
View/download PDF

33. CARING FOR THE PATIENT ON INTRAARTERIAL CHEMOTHERAPY…are you ready?

Author

Johnston, Susan and Patt, Yehuda Z.

Subjects
*DRUG therapy, *ARTERIAL catheterization, *DRUG infusion pumps
Abstract

Discusses nursing care for patients on intraarterial chemotherapy (IAC). Pros and cons of arterial catheter placement; Comparison of portable infusion pumps; Patient teaching as part of the IAC program.

Published
1981
Full Text
View/download PDF

34. Phase II study of taxol in patients with advanced gastric carcinoma.

Author

Ajani, Jailer A., Fairweather, Jackie, Dumas, Pamela, Patt, Yehuda Z., Pazdur, Richard, and Mansfield, Paul E

Abstract

Studies the efficacy of taxol in treating advanced gastric carcinoma. Advantage of chemotherapy for metastatic gastric carcinoma; Response rate in patients treated with taxol.

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results